– Preclinical data demonstrate profound B cell depletion and repopulation with predominantly naïve B cells in non-human primates, achieved through novel CD8-targeted lipid nanoparticles (tLNPs) delivering mRNA encoding a CAR
– Additional preclinical data demonstrate effective CAR engineering of T cells from healthy subjects and patients with autoimmune diseases
SAN DIEGO, CA, USA I September 26, 2024 I Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using CellSeeker™, a targeted lipid nanoparticle (tLNP) technology platform, today announced it will present preclinical data on CPTX2309, Capstan’s lead in vivo CAR-T candidate, at the American College of Rheumatology (ACR) Convergence 2024, taking place between November 14-19, 2024 in Washington, D.C.
CPTX2309, a product of Capstan’s CellSeeker™ platform, delivers an mRNA payload encoding an anti-CD19 CAR to preferentially reprogram CD8-expressing T cells. The therapeutic goal of this approach is to achieve a reset of the immune system through rapid and deep B cell depletion in both blood and lymphoid tissues, without the challenges of conventional ex vivo CAR-T.
“Capstan’s non-viral in vivo CAR-T approach is designed to bring together the unprecedented potency of CAR-T therapy with the convenience, pharmacological tunability, and scalability of a conventional biologic,” said Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D at Capstan. “Data presented at the conference will support the development of CPTX2309 for a potentially broad range of B cell-mediated autoimmune diseases, with the therapeutic goal of resetting a patient’s immune system in order to achieve a durable, drug-free clinical response.”
Presentation Details:
Abstract ID: 0835
Title: Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid Nanoparticle Encoding an Anti-CD19 CAR mRNA (CPTX2309)
Presentation type: Oral presentation
Presenting author: Haig Aghajanian, Ph.D., Co-Founder, Head and Vice President of Research, Capstan Therapeutics
Session: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Date and time: Saturday, November 16: 3:00 PM – 3:15 PM ET
Abstract ID: 0088
Title: Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR
Presentation type: Poster
Presenting author: Aric Frantz, Ph.D., Senior Director of Pharmacology and Toxicology, Capstan Therapeutics
Session: SLE – Animal Models Poster
Date and time: Saturday, November 16: 10:30 AM – 12:30 PM ET
Abstract ID: 0019
Title: A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Presentation type: Poster
Presentation author: Theresa Hunter, Ph.D., Principal Scientist, Capstan Therapeutics
Session: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
Date and time: Saturday, November 16: 10:30 AM – 12:30 PM ET
A copy of the posters and presentation will be added to the “Publications and News” section of Capstan’s website at www.capstantx.com/.
About Capstan Therapeutics, Inc. (www.capstantx.com)
Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn and X (Twitter).
SOURCE: Capstan Therapeutics
Post Views: 5,319
– Preclinical data demonstrate profound B cell depletion and repopulation with predominantly naïve B cells in non-human primates, achieved through novel CD8-targeted lipid nanoparticles (tLNPs) delivering mRNA encoding a CAR
– Additional preclinical data demonstrate effective CAR engineering of T cells from healthy subjects and patients with autoimmune diseases
SAN DIEGO, CA, USA I September 26, 2024 I Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using CellSeeker™, a targeted lipid nanoparticle (tLNP) technology platform, today announced it will present preclinical data on CPTX2309, Capstan’s lead in vivo CAR-T candidate, at the American College of Rheumatology (ACR) Convergence 2024, taking place between November 14-19, 2024 in Washington, D.C.
CPTX2309, a product of Capstan’s CellSeeker™ platform, delivers an mRNA payload encoding an anti-CD19 CAR to preferentially reprogram CD8-expressing T cells. The therapeutic goal of this approach is to achieve a reset of the immune system through rapid and deep B cell depletion in both blood and lymphoid tissues, without the challenges of conventional ex vivo CAR-T.
“Capstan’s non-viral in vivo CAR-T approach is designed to bring together the unprecedented potency of CAR-T therapy with the convenience, pharmacological tunability, and scalability of a conventional biologic,” said Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D at Capstan. “Data presented at the conference will support the development of CPTX2309 for a potentially broad range of B cell-mediated autoimmune diseases, with the therapeutic goal of resetting a patient’s immune system in order to achieve a durable, drug-free clinical response.”
Presentation Details:
Abstract ID: 0835
Title: Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid Nanoparticle Encoding an Anti-CD19 CAR mRNA (CPTX2309)
Presentation type: Oral presentation
Presenting author: Haig Aghajanian, Ph.D., Co-Founder, Head and Vice President of Research, Capstan Therapeutics
Session: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Date and time: Saturday, November 16: 3:00 PM – 3:15 PM ET
Abstract ID: 0088
Title: Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR
Presentation type: Poster
Presenting author: Aric Frantz, Ph.D., Senior Director of Pharmacology and Toxicology, Capstan Therapeutics
Session: SLE – Animal Models Poster
Date and time: Saturday, November 16: 10:30 AM – 12:30 PM ET
Abstract ID: 0019
Title: A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Presentation type: Poster
Presentation author: Theresa Hunter, Ph.D., Principal Scientist, Capstan Therapeutics
Session: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
Date and time: Saturday, November 16: 10:30 AM – 12:30 PM ET
A copy of the posters and presentation will be added to the “Publications and News” section of Capstan’s website at www.capstantx.com/.
About Capstan Therapeutics, Inc. (www.capstantx.com)
Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn and X (Twitter).
SOURCE: Capstan Therapeutics
Post Views: 5,319
